Duchenne muscular dystrophy (DMD) is a genetic condition that causes progressive muscle weakness, typically becoming noticeable in early childhood and worsening over time. It affects roughly 1 in 3,500 to 5,000 male births worldwide, making it the most common form of muscular dystrophy. DMD primarily affects boys because the gene responsible sits on the X chromosome, though the condition touches entire families.
Why Muscles Break Down Without Dystrophin
Every time a muscle contracts, its outer membrane takes a beating. In healthy muscle cells, a large protein called dystrophin acts as a shock absorber, anchoring the internal skeleton of the cell to the membrane and the tissue surrounding it. This connection keeps the membrane stable during repeated cycles of contraction and relaxation.
In DMD, the gene that produces dystrophin is mutated, so the protein is either absent or non-functional. Without that stabilizer, muscle cell membranes become fragile. Each contraction tears tiny holes in the membrane, allowing damaging substances to flood in and essential contents to leak out. The body tries to repair the damage, but over time the repair process can’t keep up. Muscle fibers die and get replaced by scar tissue and fat, which is why affected muscles can look unusually large (a phenomenon called pseudohypertrophy) even as they grow weaker.
How DMD Is Inherited
DMD follows an X-linked recessive inheritance pattern. Boys have one X and one Y chromosome, so a single defective copy of the DMD gene is enough to cause the disease. Girls have two X chromosomes, meaning a working copy on the second X typically compensates. A woman carrying one altered copy is called a carrier and usually has no symptoms, though about 20 percent of carriers do develop some degree of muscle weakness or cardiac problems.
Each pregnancy for a carrier woman carries a 50 percent chance of passing on the altered gene. That translates to a 25 percent chance of having a son with DMD and a 25 percent chance of having a daughter who is a carrier. Notably, about one-third of DMD cases arise from new, spontaneous mutations with no prior family history, so the diagnosis can come as a complete surprise.
Early Signs Parents Notice
Most boys with DMD appear healthy at birth. The first hints usually emerge between ages 2 and 5, when a child falls behind motor milestones or moves differently than peers. Common early signs include a wide-based, waddling gait, walking on the toes, difficulty running or jumping, and frequent falls. Many children develop an exaggerated curve in the lower back as their body compensates for weakening hip and pelvic muscles.
One hallmark clue is the way a child gets up from the floor. Rather than standing straight up, a boy with DMD will roll onto his stomach, push up onto all fours, then “walk” his hands up his own thighs to push himself upright. This pattern, known as the Gowers maneuver, reflects weakness in the hips and upper legs. Even in early stages, parents may notice a child pressing lightly against his thighs while standing, a subtle precursor to the full maneuver. A tendency to drop into a prone position before standing that persists past age 3 is another red flag.
How DMD Is Diagnosed
A blood test measuring creatine kinase (CK) is often the first step. CK is an enzyme that leaks out of damaged muscle cells, and in DMD it is dramatically elevated, typically 10 to 100 times the normal level. Normal CK ranges from about 35 to 232 units per liter; boys with DMD routinely show levels in the thousands, with the highest readings occurring between ages 2 and 5.
A high CK level raises suspicion, but the definitive answer comes from genetic testing. A simple blood draw can identify mutations in the DMD gene, confirming the diagnosis without the need for a muscle biopsy in most cases. Genetic testing also pinpoints the specific type of mutation, which matters because some newer therapies target particular mutations.
How the Disease Progresses
DMD follows a fairly predictable course, though the timeline varies from child to child. During the early school years, boys can still walk, run (with difficulty), and climb stairs, but strength gradually declines. The transition to a wheelchair is a major milestone. In boys who never receive steroid treatment, the median age for losing the ability to walk independently is around 10 years. With long-term corticosteroid therapy, that milestone can be delayed by 2 to 4 years, pushing the median to roughly 11 to 12 years.
Once a boy is using a wheelchair full time, attention shifts to the arms, spine, heart, and lungs. Scoliosis becomes common as trunk muscles weaken. Breathing muscles gradually lose strength, and most teens with DMD eventually need some form of ventilatory support, starting with nighttime use and potentially expanding to daytime hours. The heart is also affected: because the heart is a muscle, the absence of dystrophin leads to a form of heart disease called dilated cardiomyopathy. Regular cardiac screening with echocardiography is a core part of DMD care from the time of diagnosis onward.
Life Expectancy Today
Advances in respiratory support and cardiac care have meaningfully extended survival. Before the widespread adoption of home ventilation in the 1990s, most patients died in their late teens or early twenties from respiratory failure. Current estimates put the median life expectancy for ventilated patients at roughly 28 to 30 years, with some individuals living into their thirties and beyond. A recent meta-analysis of individual patient data estimated life expectancy at 29.9 years for those receiving ventilatory support. These numbers continue to improve as cardiac medications, respiratory devices, and overall care standards advance.
Corticosteroids as Standard Treatment
Corticosteroids remain the backbone of DMD management. They slow the loss of muscle strength, delay wheelchair dependence, and help preserve lung function. Current care guidelines recommend starting steroid therapy soon after diagnosis and continuing it long-term, with dose adjustments as needed.
The trade-offs are real. Weight gain is nearly universal, and it can be substantial. Long-term steroid use also reduces bone density, raises blood pressure, can impair growth, and increases the risk of blood sugar problems. These side effects become especially challenging after a boy stops walking, since reduced mobility compounds the metabolic effects. Families and care teams work together to balance the muscle-preserving benefits against these ongoing costs, often adjusting dosing schedules over time.
Gene Therapy and Newer Approaches
In June 2023, the FDA approved Elevidys, the first gene therapy for DMD, for children ages 4 through 5 with a confirmed DMD gene mutation. Rather than supplying a full-length copy of the enormous dystrophin gene (it is the second largest gene identified in humans), Elevidys delivers a shortened, functional version designed to produce a smaller but protective form of the protein. It is given as a one-time intravenous infusion.
Another class of treatments uses molecules called exon-skipping therapies. These work by coaxing the cell’s machinery to skip over the damaged section of the gene during protein production, resulting in a shorter but partially functional dystrophin. The limitation is that each exon-skipping drug only works for patients with mutations in a specific region of the gene, so collectively these therapies address only a subset of patients. They also require repeated dosing rather than a single treatment.
Neither gene therapy nor exon-skipping drugs are cures. They aim to produce enough functional dystrophin to slow disease progression, and long-term outcome data is still being gathered. For most families, these newer options are used alongside, not instead of, corticosteroids and comprehensive supportive care including physical therapy, respiratory support, and cardiac monitoring.